Cell therapy manufacturing must account for biological variability while consistently delivering products with defined cellular composition and functional performance. Multiparametric cell isolation provides a practical approach to controlling critical cell populations and their proportions within closed, GMP-compatible workflows.
Through two case studies, University Hospitals Erlangen and Bionoveo will explore phenotype-based cell selection in T-cell manufacturing, including approaches to controlling cellular inputs and defining CD4 composition. The webinar will also introduce Sony Biotechnology’s CGX10 Cell Isolation System in the context of these approaches and their potential applications in next-generation T-cell therapy manufacturing.
Key Attributes
In this webinar you will:
- Explore how multiparametric cell isolation can help control cellular composition in closed, GMP-compatible T-cell manufacturing workflows.
- Examine a semi-automated workflow that integrates whole-blood preparation, phenotype-based T-cell isolation, ratio control, and direct transfer for downstream expansion.
- Understand how defined CD4:CD8 ratios may influence CAR T-cell function, including tumor-cell killing and cytokine secretion.
- See how controlled cellular compositions can be produced in a closed workflow to support reproducibility and scalability.
Who Should Attend
- Cell therapy scientists
- Process development and manufacturing professionals
- Translational researchers
- Technical leaders seeking greater control, reproducibility, and scalability in CAR-T and T-cell manufacturing workflows